くすりのしおり

Injection
Revised: 4/2016

The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.
Brand name :
PACLITAXEL INJECTION 30mg "NP"
 Active ingredient:
Paclitaxel
 Dosage form:
injection
 Print on wrapping:

Effects of this medicine

This medicine inhibits tumor cell division by binding to microtubules and stabilizing to inhibit their depolymerization.
It is usually used to treat ovarian cancer, non-small cell lung cancer, breast cancer, gastric cancer, uterine corpus cancer, recurrent/distant metastatic head and neck cancer, recurrent/distant metastatic esophageal cancer, angiosarcoma, progressive/recurrent uterine cervical cancer and recurrent/refractory germ cell tumor (testicular/ovarian/extragonadal tumor).

Before using this medicine, be sure to tell your doctor and pharmacist

  • If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.
    If you have bone-marrow suppression, infections or alcohol hypersensitivity.
  • If you are pregnant, possibly pregnant or breastfeeding.
  • If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)

Dosing schedule (How to take this medicine)

  • Your dosing schedule prescribed by your doctor is ((        to be written by a healthcare professional))
  • For non-small cell lung cancer and uterine corpus cancer: In general, repeat the cycle of administering intravenous infusion for 3 hours once a day with a medicine cessation period of at least 3 weeks.
    For breast cancer: In general, repeat the cycle of administering intravenous infusion for 3 hours once a day with a medicine cessation period of at least 3 weeks. Otherwise, administer by intravenous infusion for 1 hour once a day, once a week for 6 consecutive weeks in a row as 1 course with a medicine cessation period of at least 2 weeks and repeat the course.
    For ovarian cancer: In general, repeat the cycle of administering intravenous infusion for 3 hours once a day with a medicine cessation period of at least 3 weeks. Otherwise, concomitantly with carboplatin, administer by intravenous infusion for 1 hour once a day, once a week for 3 consecutive weeks in a row as 1 course and repeat the course.
    For gastric cancer: In general, repeat the cycle of administering intravenous infusion for 3 hours once a day with a medicine cessation period of at least 3 weeks. Otherwise, administer by intravenous infusion for 1 hour once a day, once a week for 3 consecutive weeks in a row as 1 course with a medicine cessation period of at least 2 weeks and repeat the course.
    For recurrent/refractory germ cell tumor (testicular/ovarian/extragonadal tumor): In general, concomitantly with other anti-cancer medicines, repeat the cycle of administering intravenous infusion for 3 hour once a day with a medicine cessation period of at least 3 weeks.
    For recurrent/distant metastatic head and neck cancer, recurrent/distant metastatic esophageal cancer and angiosarcoma: In general, administer by intravenous infusion for 1 hour once a day, once a week for 6 consecutive weeks in a row as 1 course with a medicine cessation period of at least 2 weeks and repeat the course.
    For progressive/recurrent uterine cervical cancer: In general, concomitantly with cisplatin, repeat the cycle of administering intravenous infusion for 24 hours once a day with a medicine cessation period of at least 3 weeks.
  • The treatment schedule differs depending on other medicines to be used together or your condition. The treatment span will depend on your response to treatment after this medicine is used for a certain period of time. Specifically, please ask your doctor.

Precautions while taking this medicine

  • If bone marrow function decreases, infection and bleeding tend to occur, but you do not notice easily by yourself. Therefore, it is necessary to check the blood test regularly (1 to 2 times a week, in some cases even more) in order to detect early.
  • This medicine contains alcohol which may cause drowsiness or dizziness. Avoid driving a car or operating dangerous machinery after administering this medicine.

Possible adverse reactions to this medicine

The most commonly reported adverse reactions include rash, redness, nausea/ vomit, diarrhea, loss of appetite, stomatitis, constipation, depilation, asthenia, abdominal pain, malaise, headache, arthralgia, muscle pain, skeletal pain, back pain, fever and hot flush. If any of these symptoms occur, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
  • breathing difficulty, chest pain, cold sweat  [shock, anaphylactoid symptoms]
  • sore throat, fever, anemia [myelosuppression such as leukopenia]
  • paralysis of limbs, pain, movements disorder [peripheral neuropathy, paralysis]
  • fever, cough, breathing difficulty [interstitial pneumonia, fibrosis of the lung]
  • sudden respiratory distress [acute respiratory distress syndrome]
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.

Storage conditions and other information

For healthcare professional use only : Day Month Year

For further information, talk to your doctor or pharmacist.

Keywords Search

 

 

 

 

Advanced Search

Browse by drug name A-Z
Browse by drug name A-Z